Vaxcyte launches $1 billion equity and convertible note offering after Phase 3 vaccine success
Vaxcyte Inc. announced a simultaneous public offering of $500 million in common stock and pre‑funded warrants and $500 million in convertible senior notes due 2032, following the OPUS‑1 Phase 3 trial that met all 32 prespecified immunogenicity endpoints for its VAX‑31 pneumococcal vaccine. The raise was disclosed after market close on Monday, prompting the stock to fall between 3.7% and 10% in after‑hours and pre‑market trading. Underwriters have a 30‑day option to purchase up to an additional $75 million of each tranche.
Why it matters
The offering expands the share count and could dilute existing shareholders, as the notes could convert into roughly an additional 5% of market value, according to the company’s filing. Analysts such as Guggenheim and BTIG kept bullish price targets, indicating that the long‑term valuation of VAX‑31 remains positive despite the short‑term price pressure.
Key facts
- 1Vaxcyte announced a $1 billion capital raise split evenly between $500 million of common stock and $500 million of convertible senior notes due 2032. investing.com
- 2The offering includes a 30‑day option for underwriters to purchase up to $75 million more of each tranche. investing.com
- 3VAX‑31 met all 32 prespecified co‑primary immunogenicity endpoints in the OPUS‑1 Phase 3 trial. investing.com
- 4Shares fell 5.8% in after‑hours trading to $69.57 following the announcement. investing.com
- 5Shares fell 3.7% in pre‑market trading after the announcement. investing.com
- 6Shares fell about 10% in later trading on Tuesday. finance.yahoo.com
Open questions
- Material 1 states the stock portion represents about 5% of market value, while material 3 suggests the combined equity and convertible portion could total roughly 10% of market value if fully converted.
Summary written by AlphAI from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.